Tonix Pharmaceuticals Holding Corp Total Assets
Tonix Pharmaceuticals Holding Corp total assets. Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) holds total assets worth $277.17 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tonix Pharmaceuticals Holding Corp market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Tonix Pharmaceuticals Holding Corp (2008–2025)
Total assets of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. This chart illustrates how Tonix Pharmaceuticals Holding Corp's total assets have evolved over time, based on quarterly financial data. See TNXP stock price and chart for real-time trading data and today's change.
Tonix Pharmaceuticals Holding Corp - Asset Composition Analysis
Tonix Pharmaceuticals Holding Corp Total Assets Breakdown (December 2025)
Tonix Pharmaceuticals Holding Corp total assets breakdown as of December 2025. Tonix Pharmaceuticals Holding Corp's total assets of $277.17 Million consist of 82.6% current assets and 17.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.9% |
| Accounts Receivable | $9.76 Million | 3.5% |
| Inventory | $6.01 Million | 2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $120.00K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Tonix Pharmaceuticals Holding Corp current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tonix Pharmaceuticals Holding Corp's current assets represent 82.6% of total assets in 2025, a decrease from 100.0% in 2008.
- Cash Position: Cash and equivalents constituted 74.9% of total assets in 2025, down from 88.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 3.5% of total assets.
Tonix Pharmaceuticals Holding Corp Competitors by Total Assets
Key competitors of Tonix Pharmaceuticals Holding Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Tonix Pharmaceuticals Holding Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.42 | 6.50 | 28.73 |
| Quick Ratio | 7.23 | 6.04 | 28.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $198.04 Million | $100.69 Million | $167.14 Million |
Tonix Pharmaceuticals Holding Corp - Advanced Valuation Insights
This section examines the relationship between Tonix Pharmaceuticals Holding Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 70.2% |
| Total Assets | $277.17 Million |
| Market Capitalization | $72.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tonix Pharmaceuticals Holding Corp's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tonix Pharmaceuticals Holding Corp's assets grew by 70.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tonix Pharmaceuticals Holding Corp (2008–2025)
The table below shows the annual total assets of Tonix Pharmaceuticals Holding Corp from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $277.17 Million | +70.16% |
| 2024-12-31 | $162.89 Million | +5.46% |
| 2023-12-31 | $154.46 Million | -31.56% |
| 2022-12-31 | $225.69 Million | -6.31% |
| 2021-12-31 | $240.90 Million | +145.36% |
| 2020-12-31 | $98.18 Million | +574.43% |
| 2019-12-31 | $14.56 Million | -44.69% |
| 2018-12-31 | $26.32 Million | -1.63% |
| 2017-12-31 | $26.75 Million | -2.75% |
| 2016-12-31 | $27.51 Million | -41.49% |
| 2015-12-31 | $47.02 Million | +18.91% |
| 2014-12-31 | $39.54 Million | +352.63% |
| 2013-12-31 | $8.74 Million | +312.62% |
| 2012-12-31 | $2.12 Million | +397.64% |
| 2011-12-31 | $425.45K | +9100.82% |
| 2010-12-31 | $4.62K | -64.52% |
| 2009-12-31 | $13.03K | -71.62% |
| 2008-12-31 | $45.91K | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more